Clinical Trials

Neuroendocrine Tumors

NCT01841736 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

171 enrolled 15 charts

Neuroendocrine Tumors

NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04394858 2026-03-18

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

46 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04569591 2026-03-18

DDAVP for Pituitary Adenoma

Phase NA Recruiting

22 enrolled

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT05500391 2026-03-18

SUR-CAN

CNSEndocrineGastrointestinalNETSarcoma

88 enrolled

Carcinosarcoma, Glioma, Seminoma, Adenocarcinoma, Clear Cell, Carcinoma, Small Cell, Sex Cord-Gonadal Stromal Tumors, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT05724108 2026-03-18

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

94 enrolled

Neuroendocrine Tumors

NCT05773274 2026-03-18

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

100 enrolled

Metastatic Digestive System Neuroendocrine Tumor G1

NCT06406465 2026-03-18

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

60 enrolled

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06487481 2026-03-18

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Phase 1 Recruiting

32 enrolled

Adrenocortical Carcinoma

NCT06900595 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

48 enrolled

Phase 2/3 Not yet recruiting

Adrenocortical Carcinoma

NCT07444723 2026-03-18

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

193 enrolled

Parathyroid Neoplasms, Multiple Endocrine Neoplasia Type 1, Hyperparathyroidism, Primary

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT04665739 2026-03-17

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

70 enrolled

Phase 1 Active not recruiting

Advanced Lung Neuroendocrine Tumor

NCT04750954 2026-03-17

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

29 enrolled

Neuroendocrine Tumors

NCT00001238 2026-03-16

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

5,000 enrolled

EndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms, Pheochromocytoma

NCT00001452 2026-03-13

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Completed

1,387 enrolled

Cushing Syndrome, Peutz-Jeghers Syndrome, Pituitary Neoplasms, Carney Complex

NCT00107289 2026-03-13

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

200 enrolled

CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT06353529 2026-03-12

POPPY

Phase 4 Recruiting

108 enrolled

Pain, Postoperative, Pituitary Diseases

NCT00001160 2026-03-11

Studies on Tumors of the Thyroid

2,500 enrolled

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00923026 2026-03-11

Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

Enrolling by invitation

1,150 enrolled

DermatologicEndocrineNET

Adenocarcinoma, Carcinoma, Melanoma, Neuroendocrine Tumors

NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

133 enrolled

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT03753919 2026-03-11

DUTHY

Phase 2 Terminated

79 enrolled 25 charts

Phase 1 Active not recruiting

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT06379217 2026-03-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

31 enrolled

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT07140757 2026-03-11

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers

50 enrolled

Thyroid Cancer, Papillary

NCT07463625 2026-03-11

PiTFET

20 enrolled

Pituitary Diseases, Pituitary ACTH Hypersecretion, ACTH-Secreting Pituitary Adenoma

NCT00001595 2026-03-10

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

2,000 enrolled

Combined Pituitary Hormone Deficiency, Congenital Abnormalities, Acromegaly, Gigantism, Prolactinoma, Pituitary ACTH Hypersecretion, Carcinogenesis

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

Phase NA Active not recruiting

Neuroendocrine Tumors

NCT04175678 2026-03-10

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

100 enrolled

EndocrineOther

Motor Activity, Obesity, Multiple Endocrine Neoplasia Type 1

NCT05160480 2026-03-10

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Enrolling by invitation

9 enrolled

BreastEndocrineGenitourinaryNET

Breast Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors

NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1/2 Recruiting

66 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

141 enrolled

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

Phase 1/2 Recruiting

150 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07460232 2026-03-10

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

50 enrolled

Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT01109420 2026-03-09

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

500 enrolled

Non-Medullary Thyroid Cancer

NCT03374215 2026-03-09

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

1,150 enrolled

ACTH Syndrome, Ectopic, Adrenal Gland Neoplasms, Bone Diseases, Metabolic, Cardiovascular Diseases, Hyperaldosteronism, Hyperinsulinism, Hypertension

NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Active not recruiting

11 enrolled

Neuroendocrine Tumors

NCT06957691 2026-03-09

Fezo-ADT

60 enrolled

EndocrineGenitourinary

Adenocarcinoma, Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1, Hot Flashes

NCT07456878 2026-03-09

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Phase 1 Recruiting

5 enrolled

Pituitary Neoplasms

NCT07458906 2026-03-09

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Phase NA Recruiting

60 enrolled

Carcinoma, Neuroendocrine

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

120 enrolled

Thymus Neoplasms, Neuroendocrine Tumors

NCT05988918 2026-03-06

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

EndocrineGastrointestinalNET

66 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Somatostatinoma, Carcinoma, Adenosquamous

NCT06784752 2026-03-06

NETTER-3

Phase 3 Recruiting

240 enrolled

EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Phase 2 Completed

20 enrolled

CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

NCT05604963 2026-03-05

HoT

Phase NA Recruiting

456 enrolled